LANSOPRAZOLE by Novartis is compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the (h , k )-atpase enzyme system at the secretory surface of the gastric parietal cell. Approved for symptom relief of active duodenal ulcer [see clinical studies ( ], symptom relief of active benign gastric ulcer [see clinical studies ( ], including zollinger-ellison syndrome. First approved in 2010.
Drug data last refreshed 11h ago
compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the (H , K )-ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the parietal cell, lansoprazole…
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Maintenance of Healing in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 Months
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
The Efficacy and Safty of Proton Pump Inhibitor (Lansoprazole)
Worked on LANSOPRAZOLE at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.